Parsplana Vitrectomy Alone Versus Parsplana Vitrectomy Combined With Phacoemulsification for The Treatment of Rhegmatogenous Retinal Detachment: A Randomized Study

Paolo Mora (✉ paolo.mora@unipr.it)
Institute of Ophthalmology https://orcid.org/0000-0001-7133-8250

Stefania Favilla
University of Parma: Universita degli Studi di Parma

Giacomo Calzetti
University of Parma: Universita degli Studi di Parma

Giulia Berselli
University of Parma: Universita degli Studi di Parma

Lucia Benatti
University of Parma: Universita degli Studi di Parma

Arturo Carta
University of Parma: Universita degli Studi di Parma

Stefano Gandolfi
University of Parma: Universita degli Studi di Parma

Salvatore Antonio Tedesco
University of Parma: Universita degli Studi di Parma

Research article

Keywords: Rhegmatogenous retinal detachment, parsplana vitrectomy, phacovitrectomy, retinal detachment recurrence, cataract

DOI: https://doi.org/10.21203/rs.3.rs-294145/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

BACKGROUND: To compare parsplana vitrectomy (PPV) with and without phacoemulsification to treat rhegmatogenous retinal detachment (RRD).

DESIGN: parallel, randomized trial.

METHODS: subjects aged 48 - 65 years with RRD in a phakic eye due to superior retinal tears with an overall extension of retinal breaks < 90° underwent to PPV alone (group A); or PPV plus phacoemulsification (phacovitrectomy, PCV, group B). Post-operative follow-up visits occurred at 1 week, 1 month (m1), 3 months (m3), and 6 months (m6) after surgery. The main outcome was the rate of retinal reattachment. Secondary outcomes included best-corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CMT), and cataract progression (in the lens-sparing [PPV-alone] group).

RESULTS: in this initial phase of the study a total of 59 patients (mean age: 55 years, 59 eyes) were enrolled: 29 eyes in group A and 30 eyes in group B. Both groups had similar gas tamponade. During the follow-up there were three cases of RRD recurrence in group A and one in group B. The relative risk of recurrence in group A was 3.22 times higher but the difference was not significant (p = 0.3). The two groups were also similar in terms of BCVA and IOP variation. At m3, CMT was significantly higher in group B (p = 0.014). In group A, cataract progression was significant at m6 (p = 0.003).

CONCLUSIONS: In a cohort of RRD patients selected according to their preoperative clinical characteristics, PPV was comparable to PCV in terms of the rate of retinal reattachment after 6 months.

TRIAL REGISTRATION: ISRCTN15940019

Date registered: 15/01/2021 (retrospectively registered)

Background

Rhegmatogenous retinal detachment (RRD) is a potentially blinding ocular disease resulting from the separation of the neurosensory retina from the retinal pigment epithelium because of formation of a retinal break and entry of fluid from the vitreous cavity to the subretinal space.[1] The incidence of RRD has been reported to be between 6.3 and 17.9 per 100,000 population.[2] RRD is largely more common in adults with myopia or pseudophakic eyes but it can affect younger patients, particularly those with risk factors such as ocular trauma or hereditary ocular abnormalities.[3-5] Although scleral buckling surgery still plays a role in the management of some types of RRD, in recent years there has been a trend toward parsplana vitrectomy (PPV) as the primary procedure, maybe also because young surgeons are particularly familiar with this latter technique.[6] For phakic RRD, PPV can be performed with or without removing the lens, and previous studies have reported advantages and drawbacks for both approaches. Phacovitrectomy (PCV), i.e., phacoemulsification combined with PPV, is associated with: a) enhanced retinal visualization during posterior segment surgery; b) better access to the vitreous base allowing for a
more extensive vitrectomy and endolaser treatment (thereby ensuring more extensive gas filling and better tamponade of retinal breaks; and c) reduced risk through avoiding the need for a second surgery, which can be technically challenging due to the lack of vitreous support.[7,8] However, there are also disadvantages of PCV: a) there is a risk of postoperative refractive errors, especially in macula-off cases; b) iatrogenic anisometropia is frequent in myopic subjects; and c) it can lead to removal of a largely healthy organ in cases of no/mild cataract with residual accommodative function.[9-11] The risk-benefit ratio of the lens-sparing procedure (i.e. PPV-only) is the reverse of that of PCV.

PPV and PCV have been compared for the treatment of RRD in several recent large, retrospective studies. [11-15] One prospective series included two groups that underwent vitreoretinal surgeries for various pathologies.[16] In this report, we present the results of a prospective randomized trial comparing PPV and PCV for RRD. Retinal reattachment at the 6-month follow-up after a single procedure was the main outcome. Several other clinical and anatomical parameters were also evaluated.

**Methods**

*Patients and study design*

This hospital-based, parallel randomized study compared PPV with and without phacoemulsification of the lens for the treatment of RRD. This study, which was approved by the local Ethics Committee (registration number 569/2018) and adhered to the tenets of the Declaration of Helsinki and CONSORT guidelines, was conducted in the Ophthalmology Unit of the University Hospital of Parma (Parma, Italy) between December 2018 and November 2019. The inclusion criteria were as follows: 1) aged 48–65 years with RRD in phakic eyes; 2) the presence of up to three separate retinal tears within the superior 180° of the retinal circumference with an overall extension of retinal breaks < 90°; 3) proliferative vitreoretinopathy (PVR) not exceeding the grade B according to the updated classification of 1991;[17] and 4) lens opacity not exceeding the first grade of each category of the Lens Opacities Classification System III (LOCS III) scale.[18] The exclusion criteria were previous surgery in the affected eye (excluding corneal refractive procedures), current use of topical hypotensive medications, documented diabetic or hypertensive retinopathy, age-related maculopathy, and optic nerve vascular pathologies. The trial used equal randomization (1:1 for the two groups).

Patients scheduled for vitreoretinal surgery to treat RRD provided general and ocular medical history data, including current refractive correction, and underwent a slit lamp examination with applanation tonometry, lens opacity grading, and fundoscopy under mydriasis. Written informed consent was obtained from patients fulfilling the study criteria. All affected eyes of enrolled patients underwent preoperative optical coherence tomography (OCT; Cirrus HD-OCT 4000; Carl Zeiss Meditec, Dublin, CA, USA). In cases with macula-on RRD, the axial length (AL) was evaluated using optical biometry (IOL-Master; Carl Zeiss Meditec). In cases with macula-off RRD, AL was measured using the combined vector-A/B-scan ultrasound biometry (B-scan Plus; Accutome, Malvern, PA, USA) technique.[19] The optimal intraocular lens (IOL) power was calculated using the Sanders–Retzlaff–Kraff/theoretical (SRK/T)
formula, for all eyes except those with prior refractive surgery (for which we used the Barrett Universal II formula). At this stage, the subjects were sequentially assigned to one of the two treatment groups basing on the date of enrollment. All surgeries were performed by the same two surgeons (PM/ST) under general anesthesia or local anesthesia with sedation, according to the patient's general condition and predisposition. All patients were hospitalized on the day of surgery and discharged the next day after slit lamp examination of the anterior segment, fundus evaluation, and tonometry of the operated eye.

**Group A: Lens-sparing technique (PPV-only).** PPV was performed using a binocular indirect ophthalmomicroscope (BIOM; Oculus, Wetzlar, Germany) for noncontact, wide-angle surgery. A 25-gauge trocar with a valved cannula (Alcon Laboratories Inc., Fort Worth, TX, USA) was inserted transconjunctivally in the inferotemporal, superotemporal, and superonasal quadrants, 4 mm posterior to the limbus. A 27-gauge twin bullet lights system was inserted at around the 1 and 11 o'clock meridians. This allowed the surgeon to independently indent the periphery externally with one hand and perform peripheral vitreous shaving with the other. All surgeries were performed using the Constellation Vitrectomy System (Alcon Laboratories Inc.). During the procedure, core vitrectomy was initially performed. When the posterior hyaloid was attached to the posterior pole, detachment was performed using the vitreous probe at an aspiration rate of 400 mmHg, without cutting. In all cases, visualization of the posterior hyaloid was facilitated by 0.05 mL of preservative-free triamcinolone acetonide (Taioftal®; Sooft Italia, SpA, Montegiorgio, Italy). Perfluorocarbon liquid (PFCL) was injected intravitreally up to around 2 disc diameters from the posterior edge of the less peripheral tear, to promote internal subretinal fluid drainage during fluid-air exchange. Cryopexy was used to freeze areas around the retinal breaks and those adjacent to the sclerotomies. Fluid–air exchange was then performed to remove all balanced saline solution and PFCL before gas tamponade (C3F8 at 18%). At the end of surgery, all trocars were removed and sutures were placed according to the watertight nature of the holes. A subconjunctival injection of 0.2 mL of gentamicin and dexamethasone solution was administered before the lid speculum was removed.

**Group B: Phacovitrectomy.** Standard phacoemulsification was performed systematically before the PPV through a 2.2-mm clear corneal incision, with implantation of a hydrophobic, acrylic, foldable monofocal IOL (TECNIS®; Johnson & Johnson, New Brunswick, NJ, USA). The subsequent vitrectomy procedure was the same as that mentioned above, except that argon endolaser treatment of the breaks was used instead of cryopexy.

**Outcomes and follow up**

Primary study outcome: the anatomical success rate, defined as retinal reattachment 6 months after primary surgery without reoperation (postoperative argon laser treatment on areas considered to be at risk for new rhegmatogenous events was not considered as reoperation).
Secondary outcomes: final best-corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CMT) and progression of the cataract (group A only). For the statistical analysis, this latter parameter was expressed as the sum of the scores for the affected eye on every LOCS III scale category at the follow-up visits.

Follow-up: all parameters defining the primary and secondary outcomes were assessed during postoperative follow-up visits scheduled at 1 week (w1), 1 month (m1), 3 months (m3), and 6 months (m6) after surgery (± 7 days starting from m1). Patients with retinal detachment recurrence dropped out of the study and were managed according to the most suitable procedure. Adverse events (related or unrelated to the study) occurring between study visits were recorded as having occurred at the time of the closest scheduled visit. An IOP value ≥ 25 mmHg was taken to indicate the use of hypotensive drugs. OCT evidence of cysts or diffuse edema in the macular region necessitated subtenon injection of triamcinolone acetonide (Taioftal®; Soff Italia), unless clinically contraindicated.[20] Laser treatment was performed postoperatively if new tears occurred and postoperative examination showed an insufficient effect of primary laser treatment or cryopexy.

Sample size and statistical analysis: a difference up to 10% in the achieving of the primary outcome was assumed as non-inferiority margin between the two procedures (i.e. δ = 10%). By accepting a type I error of 5% and a type II error of 20% (i.e. a study power of 80%), a total sample size of 50 units (2 groups of 25 units) was required. The units correspond to the eyes assigned to each treatment group. The software used for the calculations is G * Power 3.1.9.

Demographics and ocular baseline findings are given as percentages for categorical data and as mean ± standard deviation (SD) for continuous variables. All analyses were performed using R software .[21] The primary outcome (retinal reattachment) was evaluated using Kaplan-Meier analysis and the log-rank test; the relative risk (RR) of detachment was determined for groups A and B. The baseline group comparison for normally distributed variables was performed using Student’s t-test, and proportions were compared using Fisher’s exact test. All between- and within-group follow-up analyses were based on repeated-measures ANOVA models. For post hoc contrast analysis, Fisher’s least significant difference test (95% family-wise confidence level) was applied (Table 2). For all variables, p-values < 0.05 were considered significant.

Results

Fifty-nine eyes of 59 patients (36 men and 23 women, mean age: 55 years) were enrolled for the study and randomly allocated to group A (29 eyes) or group B (30 eyes). Demographics and preoperative ocular findings are provided in Table 1. At baseline, the two groups showed no statistical difference.

Preoperatively, the presence of an incomplete posterior vitreous detachment (PVD) was observable in 8 eyes; of these 5 had PPV and 3 PCV. All surgeries were uneventful in terms of complications related to the lens (no capsule ruptures, crystalline lens contact, or IOL displacement), endophthalmitis, and procedures
on the posterior segment. At the 1-day postoperative visit, the retina was attached in all operated eyes, although there were some cases of corneal edema and mild hyphema.

RRD recurred in three cases in group A (two after 1 month and one after 3 months) and in one case in group B (at the m3 visit). The log-rank test revealed that the RR of RRD recurrence was 3.22 times higher in group A than in group B, but the difference was not significant (p = 0.3; Figure 1).

Regarding the secondary outcomes, both within- and between-group (Table 2) analyses were performed. In both groups, BCVA improved over time and was thus significantly better at m6 than at w1 (p = 0.009 and p = 0.020 in groups A and B, respectively). The final mean BCVA in group A (0.19 ± 0.18 logMAR, Snellen equivalent of 20/32) was better than in group B (0.28 ± 0.23 logMAR, Snellen equivalent of 20/40), but not significantly (p = 203). The two groups differed in terms of the increase in BCVA over time (p = 0.016). In group A, the improvement was significant between w1 and m1 (p = 0.046) and continued to improve thereafter, but not significantly. In group B, gradual improvement in the BCVA was seen throughout the follow-up, but only m6 and w1 were significantly different (p < 0.001).

Regarding the postoperative IOP values, a significant group difference was detected only at w1 higher in group A (p < 0.001). In group A, up to m3 the postoperative IOP was significantly higher than that preoperatively. Starting from m3, hypotensive treatment was prescribed in three eyes in group A, while it was administered in two eyes in group B starting from m1. In all cases, satisfactory IOP control was achieved.

The CMT, assessed based on the central subfield thickness as revealed by a 512 x 128 macular cube OCT scan (Cirrus HD-OCT 4000; Carl Zeiss Meditec), could be effectively analyzed only from m1 because of the poor quality of several of the earlier images (due to corneal edema and/or intraocular gas). The CMT was significantly greater in group B than group A at m3 (p = 0.014), with the two groups showing similar values thereafter. It should be noted that subtenon steroid injections were performed in five eyes of group B with cystoid macular edema at m3 (vs. 0 eyes in group A; p=0.026 with c²-test). Due to the presence of cystoid macular edema at m6, steroid injections were performed in four eyes in group B (for the second time in three eyes), whereas no injections were required in group A (p=0.049 with c²-test).

Finally, compared to the preoperative examination, the mean total LOCS III score in group A was significantly different from baseline only at the end of the follow up (i.e., at m6; 1.31 ± 1.74 vs 0.35 ± 0.75 at baseline, p = 0.003).

Discussion

In our opinion, in some RRD cases it is unsuitable to plan PPV alone in phakic eyes, particularly when: there is a large detachment with a traumatic etiology; extensive vitreous shaving is required (up to the base); there are tears suggestive of medium- to long-term viscous tamponade; the lens is already showing opacity. Against this background, in our comparative study we included only cases that would benefit from lens-sparing surgery for RRD. The age criterion applied minimized the likelihood of advanced
cataract and absolute presbyopia; the other requirements were aimed to avoid some pre-existing RRD characteristics which correlate with lower single operation success rate, thus supporting sectorial cryopexy and an absorbable tamponade.[14,22] In the literature, the average delay between PPV (for any reason) and subsequent cataract extraction ranges from 16 to 24 months, which may justify preservation of a healthy crystalline lens at the time of PPV in selected cases.[7,23] However, the management of a RRD while preserving the lens still involves scleral buckling and often the preference with respect to vitrectomy takes into account the absence of a preexisting PVD.[6]

In our series, the rate of retinal reattachment at 6 months after PPV without cataract extraction (group A) was 89.7%; in the PCV group (group B), the rate was 96.7%. These data are consistent with prior reports.[14,15,24-26] In total, there were four cases of recurrence, three of which were from previous macula-on RRD. Group A had a RR of RRD recurrence 3.22 times higher than group B, but the difference was not significant. Interestingly, Caiado et al. reported better success rates for PCV or PPV in already pseudophakic eyes.[13] The higher RR in group A is in accordance with these results, and the lack of a significant group difference may be attributable to our selected cohort, comprising only cases with characteristics likely to account for the risk of a “non-near complete” vitreous removal. Our results are in accordance with those of Tan et al.[15] Regarding our secondary outcomes, a significant improvement in BCVA was seen at the end of follow-up in both groups. The CMT was significantly higher in group B than group A at the m3 visit, and the presence of cystoid macular edema in group B cases necessitated significantly more local steroid injections than in group A. The return to baseline CMT values in both groups at the m6 evaluation indicated that the increase therein was transient, and that the subtenon injection of Taioftal was safe and effective particularly when applied to pseudophakic eyes (group B). These results regarding CMT may accord with the postoperative inflammation described in other series of PCV.[8,16,27]

Preservation of the crystalline lens at the time of PPV in our RRD patients ensured similar outcomes to those obtained with PCV, in terms of the retinal reattachment rate and safety during postoperative management. However, the RR data for retinal detachment recurrence indicated that the possible superiority of combined surgery (PCV) should be discussed with the patient preoperatively. At the end of follow-up, the BCVA was similar between the two groups, although recovery over the follow-up was more rapid in group A. Sparing the natural lens was not associated with rapid worsening of the cataract. At the end of follow-up, lens opacity was more advanced than at the baseline, but the change was less than two LOCS III grades on average.

The limitations of this study included the relatively small sample size and short-duration follow-up preventing long-term outcome assessment. This particularly referred to eyes with preserved lens because of their potential for cataract progression and difficulties in performing the phacoemulsification in vitrectomized eyes. Nevertheless, at present this is the largest randomized study to date comparing PPV alone and PCV specifically in RRD.

**Conclusion**
To treat phakic rhegmatogenous retinal detachment, mostly in non-presbyopic patients, parsplana vitrectomy (PPV) can be performed with or without removing the lens. In this randomized study comparing PPV with versus without phacoemulsification, the difference in the rate of retinal reattachment after 6 months was not statistically significant (p = 0.3). The relative risk for retinal detachment recurrence indicated that the possible superiority of combined surgery (phacovitrectomy) should be discussed with the patient preoperatively.

**Declarations**

**Ethics approval:** all procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Medical University of Parma (“Area Vasta Emilia Nord” registration number 569/2018)

**Consent to participate:** informed consent was obtained from all individual participants included in the study.

**Consent for publication:** patients signed informed consent regarding publishing their data and photographs.

**Availability of data and material:** The data that support the findings of this study are available from the corresponding author, PM, upon reasonable request.

**Competing interests:** the authors declare that they have no competing interests.

**Funding:** No funding was received to assist with the preparation of this manuscript.

**Authors’ contributions:** PM and ST designed the work and performed surgeries; GB and LB for acquisition of data; SF for analysis of data; PM, ST, GC, AC, and SG for interpretation of data and drafting of the work. All authors read and approved the final manuscript.

**Acknowledgments:** The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/QXN1zu

**References**

1. Mitry D, Fleck BW, Wright AF, et al. Pathogenesis of rhegmatogenous retinal detachment: predisposing anatomy and cell biology. 2010;30(10):1561–1572.

2. Mitry D, Charteris DG, Fleck BW, et al. The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations. Br J Ophthalmol. 2010;94(6):678–684.
3. The Eye Disease Case-Control Study Group. Risk factors for idiopathic rhegmatogenous retinal detachment. Am J Epidemiol. 1993; 137: 749–757.
4. Weinberg DW, Lyon AT, Greenwald MJ, et al. Rhegmatogenous retinal detachments in children: risk factors and surgical outcomes. 2003;110(9):1708-13.
5. Garafalo AV, Calzetti G, Cideciyan AV, et al. Cone Vision Changes in the Enhanced S-Cone Syndrome Caused by NR2E3 Gene Mutations. Invest Ophthalmol Vis Sci. 2018;59(8):3209-3219.
6. Noori J, Bilonick RA, Eller AW. Scleral buckle surgery for primary retinal detachment without posterior vitreous detachment. 2016;36(11):2066-2071.
7. Ahfat FG, Yuen CH, Groenewald CP. Phacoemulsification and intraocular lens implantation following parsplana vitrectomy: a prospective study. Eye (Lond). 2003;17(1):16-20.
8. Smith M, Raman SV, Pappas G, et al. Phacovitrectomy for primary retinal detachment repair in presbyopes. 2007;27(4):462-467.
9. Cho KH, Park IW, Kwon SI. Changes in postoperative refractive outcomes following combined phacoemulsification and parsplana vitrectomy for rhegmatogenous retinal detachment. Am J Ophthalmol. 2014;158(2):251-256.e2.
10. Rahman R, Bong CX, Stephenson J. Accuracy of intraocular lens power estimation in eyes having phacovitrectomy for rhegmatogenous retinal detachment. 2014;34(7):1415-1420.
11. Loukovaara S, Haukka J. Repair of primary RRD - comparing parsplana vitrectomy procedure with combined phacoemulsification and parsplana vitrectomy for rhegmatogenous retinal detachment. Am J Ophthalmol. 2018;12:1449-1457.
12. Lee JY, Kim KH, Shin KH, et al. Comparison of intraoperative complications of phacoemulsification between sequential and combined procedures of parsplana vitrectomy and cataract surgery. 2012;32(10):2026-2033.
13. Caiado RR, Magalhães O Jr, Badaró E, et al. Effect of lens status in the surgical success of 23-gauge primary vitrectomy for the management of rhegmatogenous retinal detachment: the Pan American Collaborative Retina Study (PACORES) group results. 2015;35(2):326-333.
14. Guber J, Bentivoglio M, Sturm V, et al. Combined parsplana vitrectomy with phacoemulsification for rhegmatogenous retinal detachment repair. Clin Ophthalmol. 2019;13:1587-1591.
15. Tan A, Bertrand-Boiché M, Angioi-Duprez K, et al. Outcomes of combined phacoemulsification and parsplana vitrectomy for rhegmatogenous retinal detachment: a Comparative Study [published online ahead of print, 2020 Apr 3]. 2020;10.1097/IAE.0000000000002803.
16. Tayyab H, Khan AA, Javaid RMM. Clinical outcome of 23g Trans-Conjunctival parsplana vitrectomy - a prospective comparison of Phaco-Vitrectomy with only vitrectomy in phakic eyes. Pak J Med Sci. 2017;33(5):1123-1127.
17. Machemer R, Aaberg TM, Freeman HM, et al. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112(2):159-165.
18. Chylack LT Jr, Wolfe JK, Singer DM, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol. 1993;111(6):831-836.

19. Abou-Shousha M, Helaly HA, Osman IM. The accuracy of axial length measurements in cases of macula-off retinal detachment. Can J Ophthalmol. 2016;51(2):108-112.

20. Lin JM, Chiu YT, Hung PT, Tsai YY. Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior sub-tenon triamcinolone acetonide. 2007;27(2):180-189.

21. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. https://www.R-project.org/.

22. Wykoff CC, Schwartz SG, Adelman RA, et al. Primary rhegmatogenous retinal detachment repair: evidence supports an individualised approach. Br J Ophthalmol. 2015;99(11):1451-1453.

23. Feng H, Adelman RA. Cataract formation following vitreoretinal procedures. Clin Ophthalmol. 2014;8:1957-1965. Published 2014 Sep 23.

24. Ling R, Simcock P, McCoombes J, Shaw S. Presbyopic phacovitrectomy. Br J Ophthalmol. 2003;87(11):1333-1335.

25. Haugstad M, Moosmayer S, Bragadóttir R. Primary rhegmatogenous retinal detachment - surgical methods and anatomical outcome. Acta Ophthalmol. 2017;95(3):247-251.

26. Sallam AB, Donachie PHJ, Yorston D, et al. Royal College of Ophthalmologists’ National Database Study of Vitreoretinal Surgery: Report 7, Intersurgeon Variations in Primary Rhegmatogenous Retinal Detachment Failure. Retina. 2018;38(2):334-342.

27. Jalil A, Steeples L, Subramani S, et al. Microincision cataract surgery combined with vitrectomy: a case series. Eye (Lond). 2014;28(4):386-389.

### Tables

Table I: demographics and preoperative ocular findings.

| PREOPERATIVE          | Group A | Group B | p-value |
|-----------------------|---------|---------|---------|
| SEX (% females)       | 34 %    | 43 %    | 0.415   |
| AGE (years)           | 54 ± 5  | 56 ± 7  | 0.255   |
| SE (Dioptres)         | -4.27 ± 4.90 | -3.18 ± 3.83 | 0.349   |
| IOP (mmHg)            | 12.9 ± 3.5 | 14.1 ± 2.8 | 0.150   |
| MACULA ON-OFF (% ON)  | 41.38 % | 33.33 % | 0.406   |
| LENS OPACITY (LOCS III) | 0.38 ± 0.77 | 0.5 ± 0.78 | 0.553   |
Table 2: Evaluation of the secondary outcomes by between-group analyses

| Secondary outcomes | Group | Time-points |     |     |     |     |
|--------------------|-------|-------------|-----|-----|-----|-----|
|                    |       | Week 1 mean ± s.d. | Month 1 mean ± s.d. | Month 3 mean ± s.d. | Month 6 mean ± s.d. |
| BVCA (logMAR)      | A     | 0.50 ± 0.51 | 0.26 ± 0.16 | 0.20 ± 0.21 | 0.19 ± 0.18 |
|                    | B     | 0.55 ± 0.32 | 0.37 ± 0.26 | 0.31 ± 0.24 | 0.28 ± 0.23 |
| p-value            |       | n.s.        | n.s.        | n.s.        | n.s.        |
| IOP (mmHg)         | A     | 17.7 ± 7.0  | 16.1 ± 2.4  | 15.9 ± 3.0  | 15.5 ± 2.6  |
|                    | B     | 13.7 ± 3.3  | 15.4 ± 4.9  | 14.9 ± 3.3  | 14.2 ± 3.5  |
| p-value            |       | < 0.001     | n.s.        | n.s.        | n.s.        |
| CMT (mm)           | A     | -           | 279 ± 26    | 270 ± 26    | 270 ± 25    |
|                    | B     | -           | 278 ± 30    | 316 ± 118   | 297 ± 91    |
| p-value            |       | -           | n.s.        | 0.01        | n.s.        |
| LOCS III           | A     | 0.35 ± 0.75 | 0.54 ± 0.90 | 0.73 ± 1.15 | 1.31 ± 1.74*|
| p-value            |       | n.s         | n.s         | n.s         | 0.003       |
| vs baseline        |       |             |             |             |             |

SE: spheric equivalent; IOP: intraocular pressure; LOCS III: Lens Opacities Classification System III scale

BCVA: best-corrected visual acuity; IOP: intraocular pressure; CMT: central macular thickness (by Optical Coherence Tomography); LOCS III: Lens Opacities Classification System III scale